Logo image of BIAF

BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Fundamental Analysis

USA - NASDAQ:BIAF - US09076W1099 - Common Stock

2.61 USD
-0.17 (-6.12%)
Last: 10/3/2025, 8:25:18 PM
2.6013 USD
-0.01 (-0.33%)
After Hours: 10/3/2025, 8:25:18 PM
Fundamental Rating

1

BIAF gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. BIAF has a bad profitability rating. Also its financial health evaluation is rather negative. BIAF is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BIAF has reported negative net income.
In the past year BIAF has reported a negative cash flow from operations.
In the past 5 years BIAF always reported negative net income.
In the past 5 years BIAF always reported negative operating cash flow.
BIAF Yearly Net Income VS EBIT VS OCF VS FCFBIAF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

Looking at the Return On Assets, with a value of -246.03%, BIAF is doing worse than 92.72% of the companies in the same industry.
Industry RankSector Rank
ROA -246.03%
ROE N/A
ROIC N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIAF Yearly ROA, ROE, ROICBIAF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

BIAF has a better Gross Margin (29.87%) than 73.69% of its industry peers.
The Profit Margin and Operating Margin are not available for BIAF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIAF Yearly Profit, Operating, Gross MarginsBIAF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

0

2. Health

2.1 Basic Checks

BIAF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BIAF has been increased compared to 1 year ago.
The debt/assets ratio for BIAF is higher compared to a year ago.
BIAF Yearly Shares OutstandingBIAF Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
BIAF Yearly Total Debt VS Total AssetsBIAF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -23.17, we must say that BIAF is in the distress zone and has some risk of bankruptcy.
BIAF has a Altman-Z score of -23.17. This is amonst the worse of the industry: BIAF underperforms 86.19% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.17
ROIC/WACCN/A
WACC8.34%
BIAF Yearly LT Debt VS Equity VS FCFBIAF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

BIAF has a Current Ratio of 0.64. This is a bad value and indicates that BIAF is not financially healthy enough and could expect problems in meeting its short term obligations.
BIAF has a worse Current ratio (0.64) than 91.79% of its industry peers.
A Quick Ratio of 0.63 indicates that BIAF may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.63, BIAF is doing worse than 91.23% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.64
Quick Ratio 0.63
BIAF Yearly Current Assets VS Current LiabilitesBIAF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.81% over the past year.
BIAF shows a small growth in Revenue. In the last year, the Revenue has grown by 4.97%.
EPS 1Y (TTM)22.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2584.21%
Revenue 1Y (TTM)4.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-47.07%

3.2 Future

BIAF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.26% yearly.
Based on estimates for the next years, BIAF will show a very negative growth in Revenue. The Revenue will decrease by -12.63% on average per year.
EPS Next Y41.46%
EPS Next 2Y29.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.4%
Revenue Next 2Y-12.63%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

BIAF Yearly Revenue VS EstimatesBIAF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2M 4M 6M 8M
BIAF Yearly EPS VS EstimatesBIAF Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIAF. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIAF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIAF Price Earnings VS Forward Price EarningsBIAF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIAF Per share dataBIAF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

BIAF's earnings are expected to grow with 29.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.26%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIAF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOAFFINITY TECHNOLOGIES INC

NASDAQ:BIAF (10/3/2025, 8:25:18 PM)

After market: 2.6013 -0.01 (-0.33%)

2.61

-0.17 (-6.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners0.05%
Inst Owner Change0%
Ins Owners0.47%
Ins Owner Change0%
Market Cap2.58M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-32.35%
Min EPS beat(2)-66.67%
Max EPS beat(2)1.96%
EPS beat(4)1
Avg EPS beat(4)-29.08%
Min EPS beat(4)-66.67%
Max EPS beat(4)1.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.6%
Min Revenue beat(2)-17.38%
Max Revenue beat(2)-13.83%
Revenue beat(4)0
Avg Revenue beat(4)-12.73%
Min Revenue beat(4)-17.38%
Max Revenue beat(4)-9.27%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2900%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)-3500%
EPS NY rev (3m)-3500%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.04%
Revenue NY rev (1m)-6.35%
Revenue NY rev (3m)-6.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.34
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.27
EYN/A
EPS(NY)-8.26
Fwd EYN/A
FCF(TTM)-7.83
FCFYN/A
OCF(TTM)-7.75
OCFYN/A
SpS7.76
BVpS-2.16
TBVpS-4.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -246.03%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.87%
FCFM N/A
ROA(3y)-100.74%
ROA(5y)-1117.09%
ROE(3y)-194.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.62
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.85%
Cap/Sales 0.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.64
Quick Ratio 0.63
Altman-Z -23.17
F-Score3
WACC8.34%
ROIC/WACCN/A
Cap/Depr(3y)740.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2584.21%
EPS Next Y41.46%
EPS Next 2Y29.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-47.07%
Revenue Next Year-36.4%
Revenue Next 2Y-12.63%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29%
OCF growth 3YN/A
OCF growth 5YN/A